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Background: Pattern-oriented chemical profiling is increasingly being used to characterize the phytochemical
composition of herbal medicines for quality control purposes. Ideally, a fingerprint of the biological effects should
complement the chemical fingerprint. For ethical and practical reasons it is not possible to test each herbal extract
in laboratory animals or humans. What is needed is a test system consisting of an organism with relevant biology
and complexity that can serve as a surrogate in vitro system. The purpose of this study was to test the hypothesis that
the Saccharomyces cerevisiae transcriptome might be used as an indicator of phytochemical variation of closely-related
yet distinctly different extracts prepared from a single species of a phytogeographically widely distributed medicinal
plant. We combined phytochemical profiling using chromatographic methods (HPTLC, HPLC-PDA-MS/MS) and gene
expression studies using Affymetrix Yeast 2.0 gene chip with principal component analysis and k-nearest neighbor
clustering analysis to test this hypothesis using extracts prepared from the phytogeographically widely distributed
medicinal plant Equisetum arvense as a test case.
Results: We found that the Equisetum arvense extracts exhibited qualitative and quantitative differences in their
phytochemical composition grouped along their phytogeographical origin. Exposure of yeast to the extracts led to
changes in gene expression that reflected both the similarities and differences in the phytochemical composition of
the extracts. The Equisetum arvense extracts elicited changes in the expression of genes involved in mRNA translation,
drug transport, metabolism of energy reserves, phospholipid metabolism, and the cellular stress response.
Conclusions: Our data show that functional genomics in S. cerevisiae may be developed as a sensitive bioassay for the
scientific investigation of the interplay between phytochemical composition and transcriptional effects of complex
mixtures of chemical compounds. S. cerevisiae transcriptomics may also be developed for testing of mixtures of
conventional drugs (“polypills”) to discover novel antagonistic or synergistic effects of those drug combinations.
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The notion that therapeutic effects of herbal medicines
were due to the presence of a distillable “quintessence” pop-
ularized by Paracelsus and fellow alchemists some 450 years
ago [1], morphed over time into the scientific hypothesis
that pharmacological effects of herbal medicines are due to
their content of plant-derived chemical compounds (mainly
so called secondary metabolites) [2,3]. Research based on
this hypothesis conducted over the last two centuries has
led to the isolation and structural elucidation of some of the
best-known drugs and has led to the creation of modern
pharmacology and pharmacological therapy [2,4-7]. Herbal
medicine, which can therefore rightfully be considered a
progenitor of modern pharmacotherapy, has along the way
been relegated to the sidelines and its continued popularity
with the general public is viewed by many orthodox medical
professionals at best as a useless but harmless anachronism
that can be harnessed for its placebo effects or at worst as a
harmful superstition with potentially lethal adverse effects
that needs to be discouraged [8,9]. Herbal medicine will
not regain a foothold in modern science-based medicine
without clear evidence of therapeutic efficacy [10]. Such
evidence has to come from testing in randomized, double
blind clinical trials, which are considered as the “gold
standard” of clinical medicine. In addition, successful
demonstration of clinical effectiveness has to be
complemented by an appropriate theoretical framework i.e.
pre-clinical research providing a “mechanistic” basis for the
observed clinical effects. The biological “target” of the drug
and its function in the pathophysiology of the disease
should be known [11-13]. A good drug is thought to act
like Paul Ehrlich’s “magical bullet” that finds its target and
in the process “destroys” the disease process [14].
While the immense success of modern pharmacotherapy
is patently obvious, the recent shift to a preponderance of
“chronic” rather “acute” diseases and the threat of empty
drug “pipelines” has led to calls for a re-evaluation of the
current practice of drug treatment and development.
Combination therapy and so-called network and systems-
based approaches to drug discovery are being advocated
[4,15-18]. Instead of magic bullets for single targets, the
future is thought to lie in the use of both single drugs or
combinations of drugs with multi-target effects [19]. The
wheel appears to have turned full circle. What has been
regarded as its biggest problem, namely that herbal
medicines contain a myriad of chemical components
with potentially synergistic effects is now hailed as
the basis of their purported therapeutic effectiveness in
conditions, which have so far been refractory to single
drug therapy [20,21]. Elucidation of the molecular effects
and specificity of single ingredients in herbal extracts can
be difficult, but the determination of the action of every
single chemical component in phytochemically complex
extracts has been essentially elusive.Pattern-oriented chemical profiling (“fingerprinting”)
is being increasingly used to gain a more comprehen-
sive summary of herbal medicine quality [22-25]. In
comparison, component-oriented single-marker based
approaches (adapted from the mainstream pharmaceutical
industry) do not account for the complex assortment of
metabolites generally present in herbal medicine [22,23].
The pattern-oriented approach considers all detectable
constituents of a given herbal material to establish a
characteristic chemical profile without necessarily charac-
terizing all chemical constituents or their precise biological
effects. Ideally, a biological fingerprint should complement
the chemical fingerprint [26]. Preferably, fingerprints of
their biological effects should be obtained in the very
organism that will be treated with the herbal extracts. For
ethical and practical reasons, however, it is not possible to
test each herbal extract in laboratory animals or humans.
What is needed then, is a test system consisting of an
organism with relevant biology but less complexity that can
serve as a surrogate system.
The species of yeast known as Saccharomyces cerevisiae
(S. cerevisiae) is arguably the best-understood eukaryotic
organism. It is inexpensive to maintain, easy to grow and
it is classified as a “generally recognized as safe”
microorganism (it is commonly referred to as baker’s
yeast). S. cerevisiae was at the very beginning of the
“omics” revolution because it was both the first eukaryotic
organism for which the whole genome sequence was com-
pleted [27] and the first organism that was studied at the
whole transcriptome level. The nature and time course of
the transcriptional response of S. cerevisiae to a large num-
ber of environmental changes have been characterized
both qualitatively and quantitatively [28]. In addition,
scientists have generated a collection of molecular-
barcoded S. cerevisiae strains in which every single
gene has been selectively deleted [29,30]. Approxi-
mately 45% of the S. cerevisiae genes are homologous
to mammalian genes and hundreds of genes that have
been linked to diseases in humans have orthologs in
yeast [31].
In this study, we wanted to test the hypothesis that the
S. cerevisiae transcriptome might be used as an indicator
of phytochemical variation of closely-related yet dis-
tinctly different extracts prepared from a single species
of a phytogeographically widely distributed medicinal
plant. We chose the medicinal plant Equisetum arvense
commonly known as “horsetail” as model herb and the
single celled fungus S. cerevisiae as model organism for
our experiments. E. arvense is distributed worldwide
over the northern hemisphere [32]. Equisetum species
and hybrids are well understood to possess extensive
morphological, morphometric and chemotypical vari-
ation [33,34]. E. arvense is used in traditional medicine
as diuretic, anti-inflammatory, antioxidant, antidiabetic,
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dozens of manufactured products claimed to promote
general wellbeing and improve the health of hair, nails,
skin, and bone. The main constituents found within E.
arvense include alkaloids, flavonoids, phenylcarboxylic
acids, sterols, styrylpyrones, and silica [33,42-44], which
are thought to mediate the beneficial effects of this
herbal medicine. Veit and co-workers distinguished two
distinct chemotypes (chemodemes) of Equisetum based on
their phenolic chemistry [33] but there is no information
on variation of the biological and clinical effects due to
these regional variants.
Here we report that the gene expression in S. cerevisiae
exposed to globally sourced extracts of E. arvense reflected
variation in their phytochemical composition. We have
made the microarray data obtained in this study publicly
available in the Gene Expression Omnibus (GEO) database
of the National Center for Biotechnology Information of
the USA (see Methods for details).
Results
Phytochemical fingerprinting
We used 3 standard chromatography-based separation
and detection techniques of increasing complexity to
characterize the phytochemical composition of aqueous
extracts of E. arvense that were obtained from sources in
the USA (n = 7; #1 - 7), China (n = 3; #8 - 10), Europe
(n = 2; #11 - 12) and India (n = 1; # 13). The flavonoid and
phenyl carboxylic acid high performance thin-layer chro-
matography (HPTLC) profile resolved on average 9 ± 3
peaks, but only a single peak was detected in the India
sample (Figure 1A). The HPTLC profile clearly indicated a
general quantitative difference in phenyl carboxylic acid
and flavonoid concentration between the American and the
European and Chinese samples.
Chromatograms generated using high performance
liquid chromatography (HPLC) and detection using a
photodiode array (PDA) set at 280 nm contained 35 ± 7
peaks, triple the number of constituents contained in
the HPTLC profile (Figure 1B). The general trend in the
variation of in phenyl carboxylic acid and flavonoid con-
centration along phytogeographical lines was similar
to that obtained by HPTLC. The chromatograms fur-
thermore exhibited clear qualitative differences between the
samples, especially in regards to the Indian sample, which
were detectable due to the increased sensitivity of the
HPLC-PDA technique over HPTLC.
Next, we combined HPLC with mass spectrometry
(MS) to analyze the samples. HPLC-MS detected on
average 43 ± 8 peaks and revealed both qualitative
and quantitative differences between the extracts as
presented (Figure 1C).
Comparison of the different profiling techniques clearly
illustrates that the discoverable complexity of thechemical composition of herbal extracts depends on
the analytical technique used (Figure 1D).
The UV-Vis and mass spectra of peaks present in the
LC-PDA and LC-MS chromatograms respectively were
compared to the work by Veit et al [35] for tentative
identification of some of the major chromatogram peaks
(Table 1).
A representative example of how we elucidated the
structure of dicaffeoyltartaric acid and a genkwanin
acetylglucoside are presented in Additional file 1: Figure S1.
Inspection of the HPTLC and HPLC chromatograms
shown in Figure 1 appeared to suggest that the fingerprints
obtained from the Equisetum extracts grouped largely
according to their phytogeographical origin. The samples
from Europe and China were more closely similar to each
other then to the fingerprints of the Indian and American
samples. American samples, in turn, appeared to be more
closely related to each other then to the European and
Chinese samples. In order to see whether the existence of
subgroups within the data could be verified statistically, we
used the multivariate statistical techniques of principal
component analysis (PCA) and k-nearest neighbor (k-NN)
clustering analysis to quantitatively characterize differences
and similarities between the HPLC-MS fingerprints of the
E. arvense extracts (Figure 2).
PCA essentially replaces the natural, albeit potentially
subjective pattern recognition ability of the human brain by
reducing the highly complex chromatogram data into a
reduced data set, where each chromatogram is represented
by a single point, which is then plotted in the so-called
scores plot in relation to the first 2 principal components of
the entire data set. We used k-NN to colorize the PCA, by
highlighting samples that were classified into the 3 groups.
PCA not only greatly reduces the complexity of the data it
can also be used to determine which peaks and therefore
phytochemicals underlie the observed differentiation
into groups.
Figure 2A illustrates how the PCA (left panel) combined
with k-NN clustering analysis (colored circles) grouped
the chromatograms of the extracts along the lines of
their phytochemical origin (USA, red; China / Europe, blue;
India, green) with the sole exception of the European
extract #12, which was grouped with the American extracts.
Based on the similar proximity of chromatographic peaks
in the loadings plot (right panel) to the sample groups in
the scores plot, we were able to determine the peaks
generally responsible for group differentiation. Three
representative peaks have been highlighted in the
same colors as the sample groups. For example, PCA
identified dicaffeoyltartaric (chicoric) acid, which is
highlighted in Figure 2A (right panel), as a differenti-
ating factor for the Indian sample. The corresponding
peak was indeed only detected in the Indian sample
(Figure 1B and C, annotated by “a”).


















































































































Figure 1 Chromatographic characterization of the E.
arvenseextracts to identify quantitative and qualitative
differences in phenyl carboxylic acid and flavonoid composition.
(A) A TLC plate developed with natural product / polyethylene glycol
reagent, viewed under 366 nm UV light. (B) Stacked LC-PDA
chromatograms observed at 280 nm. The letter “a” denotes
dicaffeoyltartaric (chicoric) acid, which was only detected in the sample
from India. Rf: relative front. (C) Stacked LC-ESI(−)-MS chromatograms.
(D) The number of peaks detected in the TLC, LC-PDA and LC-MS
chromatograms using the msProcess peak detection software. Means
and standard deviations were calculated from biological replicates.
* Represents a statistical significance of p < 0.05.
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phytomics similarity index (PSI), we also conducted PCA
based not on the intensities of the chromatographic peaks
but on the ratio of each chromatographic peak intensity to
each other within the same sample. That is n peak intensity
values produce n n−1ð Þ2 unique ratio values. As illustrated in
Figure 2B, PCA based on the intensity ratios combined
with k-NN clustering analysis grouped extract #12 with the
other European extracts and thus grouped all extracts
according to their phytogeographical origin.Radical scavenging capacity assays
Chemometric profiling of the E. arvense extracts
demonstrated high variability in the flavonoid and
phenyl carboxylic acid content. As flavonoids and
phenolic acids have been reported to be effective free
radical scavengers and antioxidants [52], we wondered to
what degree the observed variation would be reflected in
the radical scavenging capacity of the extracts [53]. The
two main methods by which a compound can function as
an antioxidant are hydrogen atom transfer (HAT) and
electron transfer (ET) [53]. We therefore assessed the
radical scavenging capacity of the E. arvense extracts using
both HAT and ET mechanisms.
HAT reactions such as the oxygen radical absorbance
capacity assay (ORAC) are kinetic based methods, whereby
fluorescein and the antioxidant being measured compete
for peroxyl radicals generated by the thermal decom-
position of 2,2’-Azobis(2-amidinopropane) hydrochloride
(AAPH) [54]. Therefore, competition by more potent
antioxidant activity corresponds to slower fluorescein
oxidation/degradation.
ET reactions such as those using 2,2-di(4-tert-octylphenyl)-
1-picrylhydrazyl (DPPH) involve a redox reaction
between the DPPH (oxidant) and the antioxidant com-
pound being measured (reductant). DPPH is well
suited for a rapid and simple antioxidant assay as it is
commercially available and forms stable nitrogen radicals.
In its oxidised form the DPPH has an intense purple color
(λmax 515 nm) and when it is reduced it becomes yellow
Table 1 The tentative structural elucidation of several chemical constituents contained in the E. arvense samples
LC tR (min) λmax by HPLC PDA (nm) MS peaks (m/z) Tentative ID Reference
5.6 241, 328 312 (100), 179, 149 Caffeoyl tartaric acid isomer [45,46]
6.5 242, 327 312 (100) Caffeoyl tartaric acid isomer [45,46]
9.9 241, 327 312 (100), 225, 149 Caffeoyl tartaric acid isomer [45,46]
11.4 241, 328 311 (100), 179, 148 Caffeoyl tartaric acid isomer [45,46]
16.2 240, 323 367 (100), 225, 179, 135 Methyl caffeoylquinic acid [45,46]
18.5 234, 315 336 (100), 295 Caffeoylshikimic acid isomer [47]
19.8 237, 326 335 (100), 295, 179 Caffeoylshikimic acid isomer [47]
24.6 231, 283 650 (100) Quercetin or Protogenkwanin derivative [48]
26.6 241, 342 448 (100), 319 Luteolin glucoside [33,49]
28.7 265, 354 464 (100), 342, 300 Quercetin glucoside [33,48]
29.3 255, 366 579 (100), 271 Apigenin 3-O-glucoside-7-O-rhamnoside [33,50]
30.1 236, 261, 334 489, 463, 431 (100) Apigenin glucoside [33,49]
31.0 235, 269, 330 462, 410 (100) Quercetin glucoside [33,48]
31.4 235, 287 610, 301 Quercetin 3-O-glucoside-7-O-rhamnoside [50]
32.9 238, 328 473, 311 (100), 178, 149 Dicaffeoyl tartaric acid [51]
34.9 237, 261, 333 490, 445 (100) Genkwanin glucoside isomer [33,48]
41.1 288, 353 285 (100) Kaempferol derivative [33,48]
42.7 233, 270, 324 284 (100) Genkwanin glucoside isomer [33,48]
46.8 231, 288 302 (100) Quercetin / Protogenkwanin [48]
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antioxidant concentration.
Both the ORAC and DPPH methods use gallic acid as
a reference for antioxidant capacity. That is, these assays
measure how much better (or worse) the E. arvense
extracts are at being antioxidants than gallic acid.
As illustrated in Figure 3A, the Chinese and European
extracts contained approximately 5 strongly antioxidant
compounds. Peaks at 280 nm (as shown in Figure 1B;
black line in Figure 3B) that have a DPPH radical
scavenging capacity are identified by the corresponding
decrease in DPPH absorbance measured at 515 nm
(red line in Figure 3B). Overall, the ORAC and DPPH
results were comparable, indicating that the flavonoids
and phenyl carboxylic acids functioned in both the HAT
and ET mechanisms. The China #8 and USA #7 samples
showed the highest antioxidant capacity of the extracts
(Figure 3C). This was unexpected and contrary to
what was predicted by the phytochemical profiling,
which indicated that the China and European extracts
were similar to each other and distinct from the
American extracts.
Transcriptomic fingerprinting
The main goal of this study was to test the hypothesis that
the S. cerevisiae transcriptome might be developed as an
indicator of phytochemical variation of closely-related yet
distinctly different extracts prepared from a single speciesof a phytogeographically widely distributed medicinal plant.
We therefore exposed exponentially growing yeast cultures
to representative extracts from each of the three groups
identified by chemometric analysis (USA #2, n = 2
microarrays; USA #6, n = 2; USA #7, n = 2; China
#8, n = 4, Europe #11, n = 2; India #13, n = 2) and
the vehicle only (control, n = 4). We then harvested
the yeast cells to extract total RNA for analysis using
Affymetrix GeneChip® Yeast Genome 2.0 arrays. Figure 4
shows a raster plot (heatmap) of the averaged robust
multi-array average (RMA)-corrected expression values of
5900 genes (rows) on 18 microarrays (columns). Genes
and arrays were hierarchically clustered using distances
calculated from their Pearson and Spearman correlation
as indicated by the dendrograms on the left and top of the
heatmap, respectively.
The clustering results indicate that the gene expression
data not only distinguish the control samples from the
extract treated samples, but also further differentiate
between subgroups of the extract treated samples. We
next performed PCA and k-NN clustering analysis of the
gene expression data (Figure 5). Again, the analysis
separated the samples into distinct clusters largely along
phytogeographical origin and phytochemical variation,
with the exception of USA sample #6, which was grouped
with control samples (Figure 5A and B). Averaging of the
expression values from each set of arrays (control, n = 4,







































































































































Figure 3 Antioxidant activity of E. arvense extracts. (A) A TLC
plate developed in DPPH reagent, viewed under white light. Pink/purple
regions are unreacted DPPH, lighter regions are where the DPPH radical
has been scavenged by an antioxidant. After, dipping the TLC plate
was left for 10 min for the reaction to proceed fully and intentionally
“over-exposed” to reveal weak differences in radical scavenging. Rf:
relative front. (B) A representative chromatogram of the China 8 sample
using the on-line DPPH assay. The chromatogram at 280 nm (black line)
is overlaid with the DPPH absorbance at 515 nm (red line). Compounds
that have DPPH antioxidant activity are observed as a negative peak at
515 nm. (C) A comparison between the antioxidant abilities of each of


















































Figure 2 Principal component analysis (PCA) of LC-ESI(−)-MS
chromatographic peaks. Scores plots are shown on the left, the
corresponding loading plots on the right. The color and ellipses on the
scores plots denote grouping obtained from k-NN with 3 specified
clusters. The proportion of variance encompassed by each principal
component is given in parentheses. (A) The scores plot (left panel) is
based on the absolute amplitude of all 107 detected peaks, showing
that the geographical origin of the extracts is primarily associated with
the 3 specified groups (red = USA, extracts 1 to 7, blue = Europe,
extracts 11 and 12 and China, extracts 8 to 10, green = India, extract
13). The loadings plot (right) highlights peaks that are representative of
the grouping observed in the scores plot (3-hydroxyflavone for USA,
methyl caffeoylquinic acid for Europe and China, dicaffeoyltartaric
(chicoric) acid for India. (B) The scores plot (left panel) is of the 5,671
peak intensity ratios obtained from the 107 detected peaks using the
rational of Tilton and colleagues [28] showing the geographical origin
of the extracts is primarily associated with the 3 specified groups
(red = USA, blue = Europe and China, green = India). The loadings
plot (right) contained no significant information (C).
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the signal to noise ratio of the data and therefore the
diagnostic resolution (Figure 5B).
In the analysis of the gene expression data (as well as
the phytochemical data), we used PCA and k-NN
clustering as “diagnostic” tools with the goal to reduce
the complexity of the data and to classify extracts into
groups. PCA was performed by singular value decom-
position (SVD) of the centered and scaled transpose of
the data matrix [55]. SVD decomposes the data matrix
(X) into three matrices commonly termed U, D and V.
The columns of V (or rows of the transpose of V, VT)
are referred to as the principal components of X [56,57].
Using terms more evocative for biologists, Alter and
colleagues have referred to the rows of VT as the eigengenes
and the columns of U as eigenarrays [56]. The results of
SVD of the data matrix without mean centering and scaling
are illustrated in Figure 6. Inspection of the heatmap(Figure 6A) depicting the expression of the eigengenes
(rows) in each array (columns) reveals that the expression
of the first eigengene shows little variation between the
arrays. This eigengene describes the contribution of gene
expression that remains essentially constant. In contrast,
the expression levels of the remaining eigengenes show
clear differences both between the control and extract
treated samples as well as differences between the extracts
of different origin. Figure 6B illustrates the expression levels
of eigengenes 1 to 5. Each bar represents the expression
level of the respective eigengene in the arrays 1 to 18. It can
be clearly seen that the second eigengene mainly represents
the differences in gene expression between control (1 to 4)
0 0 00 8 8 8 8 2 2 7 7 66 11 13 1311
Figure 4 Hierarchical clustering of gene expression values in four control and 14 extract treated samples. Genes (rows) were clustered
based on their distance in Pearson product–moment correlation (left dendrogram); arrays (columns) were clustered based on their distance in
using Spearman rank correlation (top dendrogram). Numbers at the bottom of the figure indicate the identity of the arrays: 0, control, 8, China 8; 2,
USA2, 7, USA7; 6, USA6; 11, Europe11; 13, India13. The expression levels (log2 transformed, see Methods for details) were scaled to the row mean.
The color key indicates how the heat map colors are related to the standard score (z-score), i.e. the deviation from row mean in units of standard
deviations above or below the mean.
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highlight extract specific differences. The relative contri-
bution of the eigengene 2 to 18 to the total variation in
gene expression after eigengene 1 was filtered out is
shown in Figure 6C.
We further analyzed the microarray data using the
default linear model included with the BioConductor
“limma” package [58-60]. As robust linear modeling
of microarray results generally requires 3 or morereplicates per sample [59], we first contrasted all treat-
ment arrays (USA, n = 4; Europe/China, n = 6; India,
n =2) against the control arrays (n = 4) to generate a
table of differential expression values ranked according to
their Bonferroni-corrected p-values (p < 0.05). In order to
simulate results using a fully automated process, the 2
arrays obtained upon exposure of yeast to sample
USA #6 were not included in this analysis because

































Figure 5 PCA of the microarray results and comparison with the PCA of phytochemical data. (A) Scores plot of the PCA of four control
and 14 extract treated arrays. The numbers refer to the microarrays as follows: 8, China 8; 6, USA6; 11, Europe11, 13, India13; 2, USA2, 7, USA7.
PC1 and PC2 account for 29 % and 24 %, respectively, of the total variance in the data. (B) Scores plot of the PCA of the mean expression values
averaged over each set of arrays (control, n = 4, China #8, n = 4, Europe #11, n = 2, India #13, n = 2, USA #2, n = 2, USA #6, n = 2). PC1 and PC2
account for 36 % and 28 %, respectively, of the total variance in the data.




























































































Eigengene 1 Eigengene 2 Eigengene 4Eigengene 3 Eigengene 5
Figure 6 SVD of the gene expression data. (A) Heat map of 18 eigengenes of the entire data set. (B) Expression of the five most significant
eigengenes in the 18 eigenarrays. Each bar corresponds to the expression level of the eigengene in each array (control: 1 to 4; USA 2: 5 and 6;
USA 6: 7 and 8, USA 7: 9 and 10; China 8: 11 to 14; Europe 11: 15 and 16; India 13: 17 and 18 ) (C) Weights (eigenvalues) of the eigengenes and
their relative contribution to the entropy of the data (d = 0.65) after filtering out eigengene 1, which did not differentiate between the arrays and
can be considered to contribute only “noise” in the context of this study [56].
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http://www.biomedcentral.com/1471-2164/14/445PCA (Figure 5; inclusion of USA 6 did, however, not
significantly change the results). Figure 7A shows a
heatmap of 221 genes with significant changes in
their expression levels compared to control in all 3
phytogeographical E. arvense groups that were identified
by PCA. The E. arvense extracts elicited changes in the
expression of genes involved in mRNA translation, drug
transport, metabolism of energy reserves, phospholipid
metabolism, and the cellular stress response.
Pathway analysis revealed that the pathways producing
the major yeast phospholipids, phosphatidylserine (PS),
phosphatidylethanolamine (PE), phosphatidylcholine (PC)
and phosphatidylinositol (PI) were globally repressed
upon exposure of yeast to E. arvense extracts inde-
pendent of their phytochemical/phytogeographical
grouping (Figure 7B). All of these phospholipids are syn-
thesized through biological pathways after the transporta-
tion of choline and inositol into the yeast cell. The genes
that encode the transporters of choline (HNM1) and inosi-
tol (ITR1) were both downregulated in the presence of E.
arvense extracts. Once inside the cell, the proteins that


















Figure 7 S. cerevisiae genes affected by treatment with E. arvense ext
(p < 0.05 after Bonferroni correction) in a contrast between control (n = 4) and
according to the clustering in Figure 6A. Genes were clustered to highlight simi
relative to control on the other hand. The expression levels are scaled to the ro
(z-score), i.e. the deviation from row mean in units of standard deviations. (B) Sc
regulated by treatment with E. arvense extracts. Green arrows label downregula
differentially expressed were IPK1, inositol polyphosphate kinase; INO1, inositol-1
phosphatidylserine synthase; PSD1, phosphatidylserine decarboxylases; CHO2, p
methyltransferase, CPT1, cholinephosphotransferase; CKI1, choline kinase and UR
phosphatidate (PA), uridine monophosphate (UMP), cytidine triphosphate (CTP)
phosphate (inositol-3P), glucose-6 phosphate (glucose-6P), phosphatidylinositol
(PS), phosphatidylethanolamine (PE), phosphatidylmonomethyl-ethanolamine (P
(PC), cytidine diphosphate -choline (CDP-choline), phosphate choline (P-choline
transporters in this pathway are the myo-inositol (ITR1) and choline/ethanolami
of INO2, INO4 and OPI1 genes; the products of which form a heterodimer that
INO1, CHO1, CHO2 and OPI3 genes [61].CPT1). The genes that produce PS, PE and PC from
cytidine triphosphate (CTP) and phosphatidic acid (PA)
were downregulated (CDS1, CHO1, PSD1, CHO2 and
OPI3). In the inositol pathway, the gene responsible for the
first step in the production of inositol from glucose-6
phosphate (INO1) was also downregulated. This global
repression of the phospholipid synthetic genes was
probably the result of the downregulation of the
INO2 and INO4 genes (Figure 7B, inset). The proteins
from these genes form a complex that has been shown to
activate the expression of the INO1, CHO1, CHO2 and
OPI3 genes [61]. Therefore, the absence of these proteins
would result in decreased activation due to less binding to
the conserved cis-acting UASINO element contained in their
promoters. Repression of the OPI1 gene is counter-intuitive
to this theory since its role in the repression of the INO2
and INO4 genes would have thought it to be upregulated.
However, White and colleagues [62] have shown that this
action by the Opi1 protein is not brought about by the
amount of protein but the activation of the protein itself.
The phospholipid precursors, inositol and choline have
been shown to regulate the activity of a number of keyB
racts. (A) A heat map of 221 genes that were significantly different
all other E. arvense arrays (n = 12). Samples were averaged to yield 3 groups
larities between the different samples on the one hand and differences
w mean. The color key relates the heat map colors to the standard score
hematic representation of pathway analysis of exemplary S. cerevisiae genes
ted genes and red arrows upregulated genes. The pathway enzymes
phosphate synthase; CDS1, phosphatidate cytidyltransferase; CHO1,
hosphatidylethanolamine N-methyltransferase; OPI3, Phospholipid N-
A7, CTP synthase. The important metabolites throughout this pathway are
, cytidine diphosphate - diacylglycerol (CDP-DAG), inositol, inositol-3
(PI), phosphatidyl inositol phosphates (PIP’s), phytate, phosphatidylserine
MME), phosphatidyldimethylethanolamine (PDME), phosphatidylcholine
) and choline. The important cell membrane and cell wall (yellow bars)
ne transporters (HNM1). Inset; an inositol and choline mediated regulation























































Figure 8 An example of extract specific changes in gene
expression. A heat map of expression values of 55 significantly
regulated genes (p < 0.05 after Bonferroni correction) in a contrast
between control (n = 4) and the USA samples (n = 4) but not in the
contrast between control (n = 4) and all other Equisetum samples
(n = 12). Samples were averaged to yield 3 groups according to the
clustering in Figure 6A. The expression values (log2 transformed) were
scaled to the row mean. The color key relates the heat map colors to
the standard score (z-score), i.e. the deviation from row mean in units
of standard deviations above or below the mean. The gene symbols or
(for transcripts without gene symbol) Ensembl identifiers [65] are listed.
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pathway [63]. To investigate whether the E. arvense
extracts contained inositol and choline, extracts from
each area were analysed. A significant amount of inositol
and choline was found to be present in all the E. arvense
extract samples. For all samples the choline concentrations
were similar, whereas, there was a large difference between
the inositol concentrations (Table 2). Even though this dif-
ference was over 250-fold, the value of the lowest concen-
tration of inositol was still higher than the concentration
reported by Hirsch and Henry [64] that had an effect on
yeast gene expression. These authors found that 75 μM (14
μg/mL) of inositol completely repressed the expression of
the phospholipid synthesizing genes INO1, CHO1, CHO2
and OPI3. The lowest concentration of inositol in our
samples was 86 μM (Table 2). Thus, it is likely that the
observed repression of genes in the phospholipid pathways
in our experiments may have been due to the presence of
high levels of inositol in the E. arvense extracts.
To begin to identify extract specific changes in gene
expression, we investigated which probes were selectively
affected by the USA extracts. To this end, we performed
an analysis using a linear model contrasting the control vs.
USA and control vs. European/China samples. This
analysis generated 2 data sets containing 150 probes in
the Control-USA contrast, and 230 probes in the Control
vs. Europe/China (p < 0.05 after Bonferroni correction).
We then selected the probes that were contained only in
the USA list (n = 55) and calculated the mean of their
expression values in the control, China/Europe, India and
USA sets of microarrays. Figure 8 shows the heatmap
and hierarchal clustering of the results of this analysis. The
map reveals the group specific differences between
the samples. Preliminary pathway analysis of the data
indicated that several of the identified genes are
involved in amino acid metabolism and metabolism of
nitrogen containing compounds but the group also
contains several genes with as yet unidentified function. A
detailed analysis along the lines illustrated by this example
is in progress.Table 2 Concentrations of inositol and choline in E. arvense
samples* and concentration of inositol and choline+ added
to yeast experimental treatments
Sample *Inositol
mg/g
+ Inositol μg/mL *Choline mg/g + Choline
μg/mL
USA #2 219.83 549.57 13.22 33.05
USA #6 27.90 69.75 13.71 34.27
USA #7 10.27 25.67 7.69 19.22
CHINA #8 43.33 108.32 13.17 32.92
EUROPE #11 6.23 15.57 9.69 24.22
INDIA #13 75.70 189.25 5.17 12.92Discussion
Using simple and hyphenated chromatography techniques
we characterized extracts of E. arvense originating from
America, China, Europe and India and found that they
exhibited qualitative and quantitative differences in their
phytochemical composition but similar antioxidant cap-
acity. PCA combined with k-NN of the chromatographic
data indicated that the phytochemical differences divided
the extracts into three groups correlated with their
phytogeographical origin from America, China/Europe
or India. Supporting our hypothesis, analysis of whole
genome microarray data with PCA and k-NN showed
that the observed phytochemical grouping of the extracts
was reflected in changes in gene expression in yeast
exposed to the extracts, i.e. the S. cerevisiae transcriptome
mirrored the phytochemical data. Importantly, PCA of the
chromatographic and gene expression data is an unsuper-
vised classification method that did not require the setting
of more or less arbitrary thresholds (such “fold-increase
or -decrease in gene expression) and does not discriminate
between data points. In addition, the loadings plot can be
used to pinpoint phytochemical peaks and genes that
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clustering analysis can be used to confirm quantitatively
grouping of the extracts.
Statistical analysis of the gene expression data
using a linear model revealed that the expression of
221 genes changed significantly upon exposure of S.
cerevisiae to E. arvense extracts. Performing pathway
analysis with these genes showed that the pathways
producing the major S. cerevisiae phospholipids were
globally repressed by all tested extracts independent
of their phytochemical/phytogeographical grouping. This
observation prompted us to quantify the inositol and
choline content of the extracts, two essential components
of the major yeast phospholipids. The data revealed that
all extracts contained saturating amounts of these two
essential nutrients.
Inositol and choline containing phospholipids play an
important role in a large number of cellular processes in
health and disease. Inositol is necessary for the synthesis
of phosphoinositides, which function as lipid second
messengers implicated in signal transduction and mem-
brane trafficking [66]. Inositol has also been reported to
be critical for the growth of keratinocytes [67] consistent
with the use of E. arvense for the health of skin, hair and
nails. Dietary administration of inositol has been claimed
to have chemopreventive effects in rats [68]. Choline is
not only required for the synthesis of phosphatidylcho-
line, lysophosphatidylcholine, choline plasmalogen, and
sphingomyelin, which are essential components for all
membranes, it is also a major dietary source of methyl
groups (via the synthesis of S-adenosylmethionine) for
methylation reactions that play major roles in lipid
biosynthesis, the regulation of metabolic pathways, and
detoxification [69]. While humans can produce inositol,
choline is an essential nutrient. Yet the mean intake of
choline for most people is far below the adequate intake
[69]. The high choline content of the E. arvense extracts
(more then twice the content in egg yolks, the most
concentrated source of choline in the American diet [69])
is thus significant and supplementation of the diet with E.
arvense might provide some general health benefits.
It is interesting to note that previous phytochemical
studies of Equisetum mostly focused their general antioxi-
dant properties and on phenolic compounds, sterols and
the silica content of the herb [33,34,37,43,44,70-76]. To
the best of our knowledge, the role of inositol and choline
in relation to the beneficial effects of E. arvense has not
been investigated previously. Our results immediately sug-
gest further experiments. For example, it will be
interesting to investigate whether exposure of yeast to
saturating concentrations of choline and inositol alone
will elicit similar changes in the expression of genes
in the phospholipid synthesis pathway as observed in
the present study. Exposure of yeast to the E. arvenseextract fraction without inositol and choline will be
an interesting complementary experiment.
Transcriptomic studies have previously been conducted
both for the discovery of molecular effects of herbal medi-
cines as well as quality control purposes [26,77-80]. In two
previous studies, investigators combined phytochemical
characterization of complex extracts from multiple herbs
and microarray studies for what they called “bio-response
fingerprinting” [26,80]. The purpose of the present study
was diametrically opposite to that of the previous work.
For example, Tilton and colleagues combined chemical
fingerprinting, differential cellular gene expression and
animal pharmacology studies followed by statistical pat-
tern comparison to determine the similarity of the
chemical and bio-response fingerprints among different
manufactured batches of a multi herb preparation. These
authors used the cellular assay as a “biological detector
and the resulting genomic differential display profile after
exposure to the botanical extract … (as) a sensitive and
global biological metric …(to) validate batch similarity …”
[26] (emphasis in italics is ours). Our aim, in contrast, was
to test the hypothesis that the S. cerevisiae transcriptome
might be used as an indicator of phytochemical variation
of herbal extracts. Our data demonstrate that changes in
the S. cerevisiae transcriptome reflected the phytochemical
variation in complex extracts made from a single plant
species. Thus, the yeast transcriptome can be used as a
diagnostic tool for the classification of complex extracts
even so the overwhelming majority of the genes did not
show significant changes. While the diagnostic signals
were relatively weak, they were picked out clearly by the
PCA and cluster analyses. The functional significance of
the observed changes for yeast remains to be established
in future work.
Conclusion
Together, the results of our study serve as a proof (or better
demonstration) of principle and encourage further develop-
ment of transcriptomic assays for the characterization of
the biological effects of phytochemical variation of complex
herbal extracts. Yeast transcriptomics may also be useful
for testing of mixtures of conventional drugs (“polypills”) to
discover novel antagonistic or synergistic effects of those
drug combinations. Furthermore, it will be interesting
whether or not observed changes in the transcriptome will
be reflected at the proteome, interactome and metabolome
[81-83]. Yeast is uniquely well positioned to serve as a
model system for all types of “omics” studies.
We believe that the data presented here justify further
exploration of this and similar (e.g. mammalian cell–based)
systems of increasing yet manageable complexity useful for
the development and testing of network and systems-based
pharmacological therapies. In particular, the availability of
yeast deletion and overexpression libraries offers the
Cook et al. BMC Genomics 2013, 14:445 Page 12 of 18
http://www.biomedcentral.com/1471-2164/14/445opportunity to study systematically the interaction between
complex mixtures of small molecules and different
genomes. The unparalleled progress in our understanding
of the molecular basis of life especially in the second half
of the 20th century was driven by reductionism. There is an
increasing number of scientists, however, who feel that
complex systems may never be completely understood
from the bottom up alone, especially in biological sys-
tems, and therefore advocate holism [84,85]. Obvi-
ously, single celled organisms such as S. cerevisiae
cannot replace studies in multicellular organism but
they can be used to discover molecular markers for
monitoring in animal and human studies and are thus
a first (“reductionist”) step towards holism in pharma-
cological studies of complex mixtures of chemical
compounds.
Methods
Sources of E. arvense
LIPA Pharmaceuticals Ltd (NSW, Australia) provided
us with authenticated dried E. arvense herb and non-
standardized water extracts (USA, n = 7, 4:1 extract
ratio, dicalcium phosphate excipient; China, n = 3,
5:1 extract ratio, glucose excipient; Europe, n = 2,
5:1 extract ratio, lactose monohydrate excipient; and
India, n = 1, 4:1 extract ratio, dicalcium phosphate
excipient). The authenticity of the extracts was established
by phytochemical comparison against reference extracts
prepared from authenticated E. arvense herbs with
the traceability documents provided by each manufac-
turer and if dried raw herbs were available by genomic
authentication.
Sample preparation
We removed the excipient from the commercial extracts in
order to minimize sample variability due to the type of
excipient used and the extract-to-excipient ratio. We
weighed 4 g of each commercial extract into a 250 mL
conical flask and added 250 mL of 80% aqueous methanol.
We sonicated the solutions at 40 kHz for 1 h with
occasional stirring and centrifuged the mixture at
4000 g for 5 min to pellet the insoluble excipient. We
filtered the supernatant though a 0.45 μm PVDF
syringe filter to remove any remaining particulates.
To reduce the solution to dryness we rotary evaporated at
60°C to remove the methanol and then removed the
remaining water by freeze drying for 12 h. We stored
the product at 4°C when not in use.
Genetic authentication of the E. arvense samples
We extracted the genomic DNA from the dried aerial
part of the plant and purified it using a Qiagen DNeasy
mini plant mini kit (Victoria, Australia) according to the
manufacturer’s instructions except we used water instead ofbuffer AE. The loci we chose for genomic authentication
were the chloroplast genes maturase K (matK) and
ribulose-1,5-bisphosphate carboxylase/oxygenase large sub-
unit (rbcL) as specified by the Consortium for the Barcode
of Life (CBoL) [86]. For the PCR amplification of matK, we
used the primers ATACCCCATTTTATTCATCC in the
forward direction and TACTTTTATGTTTACGAGC in
the reverse direction as recommended by the Royal
Botanic Gardens, Kew [87]. For the PCR amplification
of rbcL we used the primers ATGTCACCACAAAC
AGAGACTAAAGC in the forward direction and GTA
AAATCAAGTCCACCRCG in the reverse direction as
recommended by CBoL [86]. We used the iProof
high-fidelity DNA polymerase PCR kit from Bio-Rad
Laboratories Inc. (NSW, Australia) for PCR amplification
as per the manufacturer’s instructions for a 50 μL reaction
with 35 cycles. The temperature program: initial
denaturation 98°C, 60 s; denaturation 98°C, 30 s;
annealing 53°C, 40 s; extension 72°C, 40 s; final
extension 72°C, 5 min. PCR products we purified
using the Qiagen QIAquick PCR Purification Kit
according to the manufacturer’s instructions except
that water is used instead of buffer AE. We sent our
PCR products to The Australian Genome Research
Facility Ltd. (NSW, Australia) for sequencing. We pro-
cessed our data using the online program Geneious™
(Biomatters, Auckland, NZ).
We were successful in using both the matK and rbcL
loci to authenticate the representative China, Europe
and India E. arvense samples. We found the matK locus
was better at differentiating E. arvense from the other
Equisetum species than rbcL, with a BLAST search of
GenBank® yielding between 97.3 - 99.9% (India and
Europe respectively) identical sites to the E. arvense
database entries using the matK products compared
to 98.9 - 100% (Europe and India respectively) for
rbcL. Although the percentage match using rbcL is
higher, the percentages are equally shared with other
Equisetum species, for example India shared the 100%
match with both E. fluviatile and E. diffusum. Numerous
single nucleotide polymorphisms (SNPs) are present in
the matK sequence for the India sample, including an
insertion between 465–472 bp not present in any other
GenBank® entries. Nucleotide alignments of the China 8,
Europe 11 and India 13 matK sequences against other
species in the GenBank® database we have presented in
Additional file 2: Figure S2. The sequences can be accessed
through from GenBank® with the accession numbers
JX392862-JX392864.
Phytochemical profiling
High performance thin layer chromatography (HPTLC)
We used a CAMAG (Muttenz, Switzerland) HPTLC sys-
tem equipped with a sample applicator and visualization
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60 F254 HPTLC plates (20 cm × 10 cm). Our HPTLC
profiling method was from Wagner et al. [88] using a
mobile phase of ethyl acetate : formic acid : glacial
acetic acid : water (100:11:11:26 mL).
We prepared working solutions of each extract by
dissolving 50 mg of the purified sample in 1 mL 80%
methanol. We then placed the solutions to sonicate
briefly to dissolve the extract and filtered them using
a 0.45 μm PVDF syringe filter. We applied 2 μl per
lane to the plate.
To visualize the flavonoid and phenyl carboxylic acid
profile, we developed the plate in natural products;
diphenylboric acid 2-aminoethyl ester and polyethylene
glycol 4000 (PEG) reagent and viewed at 366 nm.
To visualize the chemicals that scavenge the 2,2-
diphenyl-1-picryl hydrazyl (DPPH) free radical, we devel-
oped the plate in DPPH reagent (200 μg/mL in ethanol)
and visualized under white light. Chemicals that scavenge
the DPPH radical appeared yellow.
HPLC–PDA and HPLC-ESI-MS/MS
We used a Varian (California, USA) LC system equipped
with a Prostar 430 autosampler, ProStar 335 photodiode
array detector (PDA) and 1200 L quadrupole MS/MS
detector. We used an Alltech (Queensland, Australia)
Prevail C18 column (150 mm × 4.6 mm, 5 μm) with
a Phenomenex (California, USA) Security C18 guard
column (2 mm × 4 mm, 5 μm).
We prepared working solutions of each extract by
dissolving 50 mg of the purified sample in 1 mL 80%
methanol. We sonicated the solution briefly to dissolve
the extract and then filtered using a 0.45 μm PVDF
syringe filter.
We generated LC-PDA and LC-MS profiles using a
10 μL injection volume and a mobile phase flow rate
of 1 mL/min and a mobile phase consisting of 0.1%
aqueous formic acid (mobile phase A) and acetonitrile
(mobile phase B). The mobile phase profile was 10%
B for 10 min and a linear increase to 50% B between
10–63 min. We washed with 100% B for 10 min and
equilibrated with starting mobile phase for 10 min
between each analysis.
We split the post-column flow to send 80% to the PDA
and 20% to the mass spectrometer (MS) and acquired
PDA chromatograms at 280 nm. The MS was acquired in
negative electrospray ionization ((−)ESI) mode, scanning
between 70–700 m/z using a nebulization gas (nitrogen)
temperature of 400°C at 19 psi, needle voltage −3900 V at
15 μA, shield voltage −400 V, capillary voltage −100 V, and
MS detector at −1700 V.
We analyzed the inositol and choline contents of the
extracts using LC-MS in the (−)ESI mode with a selective
ion monitoring (SIM) mode at 179 m/z and 103 m/z forinositol and choline, respectively. We set the nitrogen
pressure to 20 psi at 250°C. The needle, capillary and
detector voltage were −4500 V, -45 V and −1700 V
respectively. For quantification, we used commercial
standards. The limit of detection (LOD) being 3 μg/mL
for each compound (three times method standard devi-
ation (SD) and the limit of quantification (LOQ) was 10
μg/mL (ten times method SD).
We determined the flavonoid content using LC-PDA
at 284 nm and used quercetin (3–300 μg/mL) as our
standard to construct a calibration curve to quantify the
flavonoid peaks. The total flavonoid content was 5 to
10% (w/w).
HPLC–DPPH-PDA
We visualized the chromatographic peaks that scavenge
the DPPH radial by introducing DPPH reagent (40 μg/mL
in 60% A and 40% B) into the post-column eluent using a
third pump (0.6 mL/min) and reacting the solution in a
coil (5.0 m × 0.5 mm) based on the work by Bandoniene
et al. [89]. The PDA detector acquired at both 280 nm to
monitor the chromatogram and 515 nm to monitor the
degradation of the DPPH radical.
Antioxidant assays
We used a method adapted from Blois et al. and
Molyneux et al. [90,91] to estimate the DPPH radical
scavenging capacity of the E. arvense extracts compared
to a gallic acid standard. We prepared all reagents in
80% aqueous methanol and the gallic acid standard
curve by diluting a gallic acid stock (3 mM) to form 0.3,
0.6, 0.9 and 1.5 mM working standards. Then we
prepared the samples by dissolving 1 mg of the extract
in 10 mL of 80% aqueous methanol. For the reagent
blank we used 80% aqueous methanol. In triplicate, we
pipetted 180 μL of the DPPH reagent (250 μM) into each
microtitre plate well and then 20 μL of either working
standard, sample or blank to make a total volume of 200
μL. To correct for sample absorbance (i.e. absorbance not
due to DPPH), we prepared sample blanks in triplicate by
adding 180 μL of 80% aqueous methanol to the well and
20 μL of sample. We vortexed the plate at 700 rpm
for 30 min in the dark prior to measuring absorbance at
515 nm. The sample antioxidant scavenging capacity is
reported as the gallic acid equivalent.
Oxygen radical absorbance capacity assay
We performed the oxygen radical absorbance capacity
(ORAC) assay in order to measure the ability of the
E. arvense extracts to protect fluorescein from degradation
by peroxyl radicals using the method described in the BMG
LABTECH application note 148 [92] using Trolox® as
the reference standard. We prepared all reagents in
pH 7.4 phosphate buffer (10 mM). To construct the
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(200 μM) to 12.5, 25, 50 and 100 μM working
standards. We prepared samples by dissolving 1 mg
of extract in 10 mL of 80% aqueous methanol. We
used aqueous methanol (80%) as the reagent blank.
For analysis, we used 150 μL fluorescein (10 nM) and
25 μL of either Trolox® standard, sample or blank in
each microtitre plate well which was then vortexed
for 30 min at 37°C. Rapidly we added 25 μL of the radical
generator 2,2’-azobis(2-amidinopropane)dihydrochloride
(AAPH, 240 mM) to each well and measured the plate
every 90 s (excitation 485 nm, emission 520 nm). We
compared the area under the signal degradation curves of
the samples to the Trolox® standard and the results were
given as Trolox® equivalents.
Yeast transcriptomics
We used the BY4743 (Saccharomyces cerevisiae) yeast
strain (MATα/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0
met15Δ0/MET15 LYS2/lys2Δ0 ura3Δ0/ura3Δ0) [93,94]
for our experiments. We grew the yeast to log phase
overnight at 30°C in minimal medium prepared the
same as Bell et al. [95] except that 20 mg/mL uracil was
added. We treated 25 mL of the log phase replicate
cultures (OD600 between 0.5-1.0) with dried E. arvense
extracts at a concentration of 2.5 mg/mL in the media
for 20 min. We conducted preliminary experiments to
determine the optimal dose of E. arvense extract
required for a significant effect on yeast gene expres-
sion. We tested dosages of 0.01, 1.0, 2.5, 5.0 and 10
mg/mL in the media using China 8 extract as a rep-
resentative sample. We also obtained a concurrent
growth curve with each microarray experiment. We
covered a range of CHINA-8 concentrations from 0
mg/mL to 10 mg/mL and there was no affect on
yeast growth at any of the concentrations. We chose
a concentration of 2.5 mg/mL for the final study
since 0.01 and 1.0 mg/mL produced little change in
the gene expression profile of the yeast, whereas 2.5
mg/mL resulted in approximately 1.5% of the genes
in the genome being differentially expressed by more
than 2-fold. The extracts analyzed and numbers of
biological replicates performed were: USA 2 (n = 2),
USA 6 (n = 2), USA 7 (n = 2), China 8 (n = 4),
Europe 11 (n = 2), India 13 (n = 2) and non-treated
control (n = 4). We then harvested the treated yeast
cells by centrifugation at 4000 g for 5 min. Cell
pellets were snap frozen in liquid nitrogen and stored
at −80°C prior to RNA isolation.
Isolation of yeast RNA, reverse transcription, labeling and
hybridization for microarray analysis
We used a method adapted from Winzeler et al. [29] to
extract total RNA from S. cerevisiae. We mechanicallydisrupted the frozen cell pellets and extracted total RNA
using TRIzol™ (Invitrogen, Australia) reagent according
to the manufacturer’s instructions. We purified the total
RNA using RNeasy spin columns (Qiagen, Australia);
assessed RNA quality using an Agilent Bioanalyzer 2100
(California, USA) and quantified the RNA using a
Thermo Scientific NanoDrop™ 1000 spectrophotometer
(California, USA). We submitted our purified RNA
samples to the University of New South Wales Ramaciotti
Centre for Gene Function Analysis (NSW, Australia) for
RNA transcription, labeling, hybridization, washing and
scanning of the microarray slides. We used Affymetrix
(California, USA) GeneChip® Yeast Genome 2.0 Arrays
(containing 25-mer probes with 11 probe pairs per sequence
for 5841 Saccharomyces cerevisiae transcripts and 5031
Schizosaccharomyces pombe transcripts). The microarray
results (E. arvense-treated n = 14, control n = 4) can be
accessed at Gene Expression Omnibus (GEO) http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse24888.
Statistical analysis
We used the ‘R Project for Statistical Computing’ [96] for
most of our data processing and statistical analysis. Specific
packages used with R are detailed below. The R code for
both the chemometric and biometric analyses are available
upon request from the corresponding author.
Chemometric analysis
We used the package ‘msProcess’ [97] to ‘correct’
chromatograms by removing instrumental noise, baseline
drift, identifying peaks, removing peak retention time
variations between samples and to quantify peak height.
We used principle component analysis (PCA) together
with k-nearest neighbor (k-NN) clustering analysis to
cluster samples and highlight the chemicals potentially
responsible for these differences using the ‘stats’ package
included with R. Firstly, we conducted PCA on the
corrected chromatograms and the results plotted using
the first 2 principal components (PCs). We then applied
k-NN to the first 2 PCs in order to identify samples
that cluster together. Three groups were specified
for the k-NN based on the country of origin of the
sample: 1) USA, 2) China / Europe and 3) India. We
compiled the group-specific peaks and their corre-
sponding UV and MS spectra and compared them
with those in the literature [33] to tentatively identify
the compounds.
Using the chromatogram correction technique outlined
above, we also determined the average number of peaks
detected using standard techniques commonly used in the
herbal extract industry including HPTLC, HPLC-PDA
and HPLC-MS to estimate their information content.
To determine the statistical significance (p < 0.05)
between the analytical techniques, we used one-way
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5.0d for Mac OS X [98].
Biometric analysis
We used theBioconductor [60,99] packages ‘affy’ [100],
‘affyPLM’ [101], ‘altcdfenvs’ [102], ‘annaffy’ [103], ‘limma’
[58], ‘yeast2cdf ’ [104], and ‘yeast2.db’ [105] for yeast
microarray analysis (reading the microarray *.cel files,
assessing the files for RNA degradation, relative log
expression, normalized unscaled standard error and
spatial artifacts). We processed the probe expression
values using the robust multi-array average (RMA)
model for convolution background correction, quantile
normalization and summarization [106,107]. We performed
PCA on the averaged RMA-corrected expression values
using the function prcomp in the R ‘stats’ package and SVD
using the function svd in the R ‘base’ package.
Pathway analysis
Statistical analysis of our microarray data resulted in a
list of differential genes that were common between all
E. arvense samples. We used 3 complementary web-
based platforms to evaluate our gene sets and ascertain
the cellular and molecular pathways affected in the yeast
response to treatment. Principally, we used Funspec
[108] (p-value cut-off 0.01) to analyse our gene list.
Funspec compiles information to output a classification
summary of genes and gene families that are enriched in
the ontology of 1) cellular components, 2) molecular func-
tions and 3) biological processes. Secondly, we conducted
pathway mapping of differentially expressed genes to
the annotation terms within the Kyoto Encyclopaedia
of Genes and Genomes (KEGG) [109]. This process
identified pathways and the functional locations of genes
within pathways. Thirdly, we used the Saccharomyces
Genome Database (SGD) [110] to obtain gene specific
information linking additional genes from our data set to
the pathway analysis.
Additional files
Additional file 1: Figure S1. Tentative structural elucidation of
dicaffeoyltartaric (chicoric) acid and a genkwanin acetylglucoside using
LC-ESI(-)-MS and LC-PDA. (A, B, C) the ESI(-)-MS, UV spectrum and
proposed fragmentation pattern respectively of the dicaffeoyltartaric acid
peak. (D, E, F) the ESI(-)-MS, UV spectrum and proposed fragmentation
pattern respectively of the Genkwanin acetylglucoside peak, possibly 4 or
5 -O-(6-acetyl glucoside).
Additional file 2: Figure S2. DNA bar codes of the original plant
material used to produce the China 8, Europe 11 and India 13 extracts
compared to other Equisetum species entries in the GenBank database.
Differences between the sequences are marked with a colored box.
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into the post-column eluent using a third pump coupled with photo array
detector; HPLC–PDA: High performance liquid chromatography coupled with
photo array detector; HPLC-ESI-MS/MS: High performance liquid
chromatography coupled with electrospray ionization tandem mass
spectrometry; HPTLC: High performance thin layer chromatography;
INO1: Inositol-1 phosphate synthase gene; inositol-3P: Inositol-3 phosphate;
IPK1: Inositol polyphosphate kinase gne; ITR1: Myo-inositol transporter gne;
KEGG: Kyoto Encyclopaedia of Genes and Genomes; k-NN: k nearest neighbor
clustering analysis; LC tR: Liquid chromatography retention time;
matK: Maturase K; OPI3: Phospholipid N-methyltransferase; ORAC: Oxygen
radical absorbance capacity assay; PA: phosphatidate; PC: Phosphatidylcholine;
PCA: Principal component analysis; P-choline: Phosphate choline;
PDME: Phosphatidyldimethylethanolamine; PE: Phosphatidylethanolamine;
PI: Phosphatidylinositol; PI: Phosphatidylinositol; PIP: Phosphatidyl inositol
phosphate; PMME: Phosphatidylmonomethyl-ethanolamine;
PS: Phosphatidylserine; PSD1: Phosphatidylserine decarboxylases gene;
rcbL: Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit gene;
PSI: Phytomics similarity index; RMA: Robust multi-array average; SIM: Single ion
monitoring; UMP: Uridine monophosphate.
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